Journal Scans
Malignant Peritoneal Mesothelioma—Results From the International Expanded Access Program Using Pemetrexed Alone or in Combination With a Platinum Agent
Pemetrexed Therapy for Malignant Peritoneal Mesothelioma
G Carteni, C Manegold, G Martin Garcia, S Siena, CC Zielinski, D Amadori, Y Liu, J Blatter, C Visseren-Grul, R Stahel
20090401
2009 May 1
Lung Cancer
Malignant Peritoneal Mesothelioma—Results From the International Expanded Access Program Using Pemetrexed Alone or in Combination With a Platinum Agent
Lung Cancer. 2009 May;64(2):211-218, G Carteni, C Manegold, G Martin Garcia, S Siena, CC Zielinski, D Amadori, Y Liu, J Blatter, C Visseren-Grul, R Stahel
TAKE-HOME MESSAGE
Abstract
Abstract
Aim: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided access to 109 patients with PM. Methods: This was a nonrandomized, open-label study conducted in chemo-naïve or previously treated patients with PM not amenable to curative surgery. Patients received pemetrexed (PEM) 500mg/m2 alone or with cisplatin (CIS) 75mg/m2 or carboplatin (CARBO) AUC 5 every 21 days, supplemented with standard vitamin B12, folate, and dexamethasone.Results: Response rates...
